Nattokinase for DVT

Deep vein thrombosis sends roughly 1 in 1,000 American adults to the doctor every year, and if you've found yourself researching nattokinase after a long flight, a hospital stay, or a family history of clots, you're trying to separate genuine prevention science from supplement marketing.

What Is DVT, and Why Does Prevention Matter?

Deep vein thrombosis happens when a blood clot forms in one of the deep veins of the body, almost always in the lower leg, thigh, or pelvis. According to the CDC, DVT occurs when a blood clot develops in a deep vein, most commonly in the lower leg, thigh, or pelvis, and a portion of that clot can break off and travel to the lungs as a pulmonary embolism, which requires immediate medical attention. That second part is why DVT gets taken so seriously: the clot itself is often manageable, but a piece breaking loose is a medical emergency.

This isn't a rare condition. Epidemiological research shows venous thrombosis occurs at a rate of roughly 1 per 1,000 adults annually, with about two-thirds of cases presenting as DVT, and incidence rising sharply with age — reaching 5 to 6 per 1,000 annually by age 80. Other estimates put the broader toll even higher: one clinical review found venous thromboembolism affects about 1 in 1,000 people and contributes to 60,000 to 100,000 deaths annually in the United States.

The reason prevention matters so much is that DVT is often silent until it isn't. Many clots cause mild swelling or aching that gets dismissed as a sore muscle, while others trigger no symptoms at all until a piece breaks free. That combination — common, often subtle, occasionally lethal — is exactly why people start researching options like compression stockings, movement protocols, and supplements such as nattokinase.

How Nattokinase Could Help With DVT

Nattokinase is an enzyme derived from natto, a fermented soybean food eaten in Japan for centuries, and its relevance to DVT comes down to one thing: it interacts directly with the body's clot-forming and clot-clearing machinery. A 2025 comprehensive review describes three major mechanisms — nattokinase directly dissolves fibrin by breaking it down into smaller molecules, it boosts activation of tissue plasminogen activator (tPA) to convert plasminogen into plasmin, and it cleaves cross-linked fibrin into soluble fragments.

A 2015 study published in Scientific Reports adds a layer of nuance worth understanding: nattokinase doesn't just break down existing fibrin — it also inactivates PAI-1, the protein that normally puts the brakes on the body's natural clot-dissolving system, and at an equivalent dose it proved roughly four times more effective than plasmin at dissolving a thrombus in animal models. In other words, nattokinase appears to work on both sides of the equation: helping dissolve fibrin directly, and reducing the molecular brake that would otherwise slow the body's own fibrinolysis.

A separate peer-reviewed review in Biomarker Insights found nattokinase also enhances production of urokinase from its precursor prourokinase, and blocks thromboxane-mediated platelet aggregation without producing bleeding as a side effect in the studies reviewed. None of this means nattokinase prevents DVT outright — it means there's a coherent, multi-pathway biological rationale for why researchers have studied it in this context, which is more than can be said for most supplements marketed for vein health. For background on these pathways, see our guide on how nattokinase works.

The Long-Haul Flight Study: What LONFLIT-FLITE Actually Found

The most frequently cited human trial connecting nattokinase to DVT prevention is the LONFLIT-FLITE study, published in Angiology in 2003. Researchers recruited 300 people identified as high-risk for DVT — due to factors like prior clot history, obesity, large varicose veins, or cardiovascular disease — who were about to take a 7 to 8 hour flight between New York and London. After exclusions, 204 were randomized to receive either a nattokinase-and-pine-bark-extract blend or a placebo, taken two hours before departure and again six hours later, with ultrasound scans of the leg veins performed before and after the flight.

The results were notable: none of the travelers taking the nattokinase-pine bark blend developed deep vein thrombosis, while 5.4% of the placebo group did, and the treatment group also saw a 15% decrease in lower-leg swelling compared to a 12% increase in the placebo group. Both groups were instructed to do the same isometric leg exercises and stay hydrated, so the difference in outcomes points to the supplement blend itself rather than just better self-care habits.

A few caveats matter here. First, the formula tested combined nattokinase with French maritime pine bark extract (Pycnogenol), so this trial alone can't isolate nattokinase's individual contribution. Second, this is one trial, conducted over two decades ago, in a specific high-risk travel population — it's a meaningful data point, not a guarantee that applies to everyone in every setting. If you're specifically researching circulation and blood flow more broadly, that's a related area worth exploring.

Real-World Evidence: Nattokinase in Patients With Existing Vascular Disease

Beyond the flight-specific trial, researchers have also looked at how nattokinase performs in people who already have vascular disease — a more clinically relevant population for many readers. A study published in Nutrients and indexed on PubMed Central followed 153 patients referred to a hospital vascular surgery unit, split into three groups based on their condition: deep vein thrombosis, superficial phlebitis, or venous insufficiency. Each group received standard treatment for their condition plus nattokinase.

The study documented improved clinical symptoms across all three groups, with no new cases of vascular disease recorded during follow-up and no adverse drug reactions or drug interactions observed among the 153 patients enrolled, who ranged in age from 22 to 92. Specifically for the DVT group, patients were treated with the prescription anticoagulant fondaparinux plus nattokinase added to their regimen — meaning nattokinase was used as a complement to standard anticoagulation, not as a replacement for it.

That detail is worth sitting with. This study is genuinely encouraging in that it shows nattokinase being used alongside conventional DVT treatment without apparent safety issues. But it's an open-label observational study without a placebo comparison group, which means it can tell us nattokinase didn't cause problems in this setting — it can't tell us how much of the symptom improvement came from nattokinase itself versus the prescribed anticoagulant doing what anticoagulants do. This pattern of evidence — promising mechanism, encouraging but limited human data — is consistent with what we found when reviewing nattokinase for blood clots more broadly, and for more on this specific combination question, see nattokinase as a natural blood thinner.

What the Evidence Doesn't Show Yet

Being honest about the gaps here matters more than overselling the promise. The LONFLIT-FLITE trial is the strongest piece of evidence specifically tying nattokinase to DVT prevention, and it's a real randomized controlled trial — but it tested a combination product, in one specific travel scenario, more than 20 years ago. It hasn't been widely replicated with nattokinase alone as the sole active ingredient.

The vascular disease study adds real-world context, but as an open-label trial without a placebo group, it can't isolate nattokinase's independent effect from the standard treatments patients were already receiving. And neither study addresses some of the most common real-world questions: Does nattokinase reduce DVT recurrence after a first clot? Does it help during long hospital stays or post-surgical recovery, the periods when DVT risk actually spikes? Those questions remain open, and any source telling you nattokinase is a proven DVT treatment is overstating what the current research shows.

What the evidence does support is a biologically plausible mechanism and two human studies — one randomized, one observational — that point in a consistent, encouraging direction without producing the kind of large, repeated trial base that would let a doctor confidently prescribe nattokinase as DVT prevention. That's a meaningfully different claim than "nattokinase prevents DVT," and it's the honest one.

Who Is Actually at Risk for DVT

Understanding your own risk level matters more than any single supplement decision. The CDC outlines a long list of contributing factors, noting that risk factors include injury to a vein, slow blood flow, increased estrogen, and certain chronic medical illnesses, with risk increasing further when someone has more than one of these factors at the same time. Clinically, these tend to cluster around three broader categories — sometimes called Virchow's Triad — which a peer-reviewed review describes as venous stasis, vascular injury, and hypercoagulability, with the clinical conditions most closely tied to DVT including surgery or trauma, malignancy, prolonged immobility, pregnancy, congestive heart failure, varicose veins, obesity, advancing age, and a personal history of DVT.

If long-haul travel is your specific concern, the actual numbers are more reassuring than most people assume. The CDC's travel health guidance notes that across five prospective studies of travelers on flights longer than 8 hours at low-to-intermediate VTE risk, the overall incidence was 0.5%, while the risk on flights under 4 hours was negligible. That's a useful reality check: for most healthy travelers, baseline DVT risk from flying alone is low. It rises meaningfully when flight-related immobility stacks on top of existing risk factors like a prior clot, recent surgery, hormone therapy, or significant obesity — which is exactly the population the LONFLIT-FLITE trial was designed around.

Safety, Interactions, and Who Should Not Use Nattokinase for DVT

This is the section to read most carefully if you're already on blood-thinning medication. Memorial Sloan Kettering Cancer Center's integrative medicine database states plainly that patients with coagulation disorders or those currently undergoing anticoagulant, fibrinolytic, or antithrombotic treatment should avoid nattokinase because of an increased bleeding risk when fibrinolytic supplements are combined with drugs that work through similar or overlapping pathways.

The risk isn't theoretical. A professional drug monograph documents a case report of thrombosis after a patient substituted nattokinase for warfarin following mechanical aortic valve replacement, and a separate case report of acute cerebellar hemorrhage in a patient with a prior history of ischemic stroke. The valve replacement case is a particularly important cautionary tale: that patient didn't combine nattokinase with warfarin, they replaced warfarin with nattokinase on their own — and a mechanical heart valve requires consistent, reliable anticoagulation that an unregulated supplement simply cannot guarantee.

If you're managing DVT risk and currently take warfarin, aspirin, clopidogrel, or a direct oral anticoagulant like apixaban or rivaroxaban, talk to your prescribing physician before adding nattokinase — not instead of your medication, alongside the conversation about it. The same caution applies to anyone with a bleeding disorder, recent hemorrhagic stroke, scheduled surgery, or pregnancy, where safety data simply doesn't exist yet. For a full breakdown of who should be cautious, see our dedicated nattokinase side effects guide.

How BioAbsorb Formulates Nattokinase for This Use Case

If you've decided, in consultation with your doctor, that nattokinase fits into your DVT risk management plan, formulation details matter more than most people realize. BioAbsorb's Nattokinase Enzyme delivers 100mg per capsule, standardized to 2000 FU of fibrinolytic activity per serving — consistent with the dose range used in the clinical research discussed above, including the studies cited in this article.

One formulation choice is worth explaining specifically for readers researching DVT: this product is intentionally free of vitamin K2. Natto, the traditional fermented food nattokinase comes from, naturally contains vitamin K2, which can interfere with warfarin's anticoagulant effect by promoting clotting factor synthesis. By removing K2 during processing, BioAbsorb's formulation avoids adding that variable into the mix — though this doesn't change the core caution above: nattokinase itself, K2 or not, still carries a fibrinolytic effect that can compound bleeding risk with anticoagulant medications, and that conversation with your physician still needs to happen.

The enzyme is delivered in a DRcaps delayed-release veggie capsule, designed to protect the enzyme from stomach acid before it reaches the small intestine, without the phthalates and plasticizers used in some standard enteric-coated capsules. Each batch is third-party tested for nattokinase activity, heavy metals, and microbial contaminants, and the product is manufactured in a GMP-certified Canadian facility. None of this changes the evidence base discussed above — it's simply what a quality-controlled, clinically-relevant dose of nattokinase looks like if your physician agrees it's appropriate for your situation.

Frequently Asked Questions

Does nattokinase actually prevent DVT?
The evidence is encouraging but not conclusive. A 2003 randomized trial found a nattokinase-pine bark combination prevented DVT in high-risk flyers compared to placebo, and an observational study found no safety issues when nattokinase was added to standard DVT treatment. Neither study is large enough or recent enough to call nattokinase a proven preventive treatment, and it should never replace medical care for an existing or suspected clot.

Can I take nattokinase instead of my blood thinner if I'm at risk for DVT?
No. Case reports document serious harm, including valve thrombosis, when patients substituted nattokinase for prescribed anticoagulants like warfarin. Nattokinase has not been studied as a standalone replacement for prescription anticoagulation in any condition requiring it.

Is nattokinase safe to take before a long flight?
This depends entirely on your individual risk factors and current medications. The supportive trial data involved people identified as high-risk for DVT who were not on anticoagulant therapy. If you take blood thinners, have a clotting disorder, or have other significant risk factors, talk to your doctor before flying and before adding any supplement to your routine.

How long does it take for nattokinase to have an effect on clotting?
Research on single-dose nattokinase has shown measurable changes in fibrinolytic markers within hours of ingestion, but there isn't established data on how long it takes to meaningfully affect DVT risk specifically with regular daily use. Most studies in this article used a 1,000–2,000 FU daily dose taken over weeks to months.

What's the difference between DVT and a pulmonary embolism?
DVT is a blood clot that forms in a deep vein, most often in the leg. A pulmonary embolism happens when part of that clot breaks free and travels to the lungs, which is a medical emergency. Not every DVT leads to a pulmonary embolism, but every pulmonary embolism starts as a clot somewhere else in the body.

Should I tell my doctor I'm taking nattokinase before surgery?
Yes. Because of its fibrinolytic and antiplatelet effects, nattokinase can theoretically increase bleeding risk during and after surgical procedures. Tell your surgical team about any supplement with blood-thinning properties well in advance of a scheduled procedure.

The Bottom Line

The research on nattokinase and DVT is more substantive than most supplement claims you'll encounter, but it's still early-stage: one meaningful randomized trial in travelers, one encouraging observational study in patients with existing vascular disease, and a well-documented biological mechanism connecting the two. If you're managing DVT risk, the right first step is an honest conversation with your doctor about your specific risk factors, your current medications, and whether nattokinase has a sensible place in that picture. Explore BioAbsorb's Nattokinase Enzyme to see the formulation details discussed in this article.

Research References

1. Cesarone, M.R., et al. (2003). Prevention of venous thrombosis in long-haul flights with Flite Tabs: the LONFLIT-FLITE randomized, controlled trial. Angiology, 54(5), 531-539.
2. Gallelli, G., et al. (2021). Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases. Nutrients, 13(6), 2031 (PMC8231931).
3. Pan, S., et al. (2015). A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles. Scientific Reports, 5, 11601.
4. Chen, H., McGowan, E.M., Ren, N., et al. (2018). Nattokinase: A Promising Alternative in Prevention and Treatment of Cardiovascular Diseases. Biomarker Insights, 13.
5. Comprehensive review (2025). Multifaceted microbial enzyme nattokinase: a comprehensive review on therapeutics applications, production technologies and intellectual property landscape. ScienceDirect.
6. Centers for Disease Control and Prevention. Risk Factors for Blood Clots. cdc.gov/blood-clots/risk-factors.
7. Centers for Disease Control and Prevention. Deep Vein Thrombosis and Pulmonary Embolism. CDC Yellow Book, Travel Health.
8. Cushman, M. (2007). Epidemiology and Risk Factors for Venous Thrombosis. Seminars in Hematology (PMC2020806).
9. Stone, J., et al. (2017). Deep vein thrombosis: pathogenesis, diagnosis, and medical management. Cardiovascular Diagnosis and Therapy.
10. Memorial Sloan Kettering Cancer Center. Nattokinase — Integrative Medicine Herb Database.
11. Drugs.com. Nattokinase — Professional Monograph, including Elahi et al. (2015) case report.
12. Centers for Disease Control and Prevention. About Venous Thromboembolism (Blood Clots).

About the Author

David Kimbell is a health writer, digital entrepreneur and former aerospace engineer, based in Ottawa, Canada. He loves translating complex science into clear, actionable guidance for consumers seeking evidence-based solutions.

Medical Disclaimer

This article provides educational information only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

FDA/Health Canada Statement

These statements have not been evaluated by the Food and Drug Administration or Health Canada. This product is not intended to diagnose, treat, cure, or prevent any disease.